Absci Corporation has released a corporate presentation detailing advancements in its AI-driven platform for antibody and biologic drug discovery. The presentation highlights the company's integrated approach, combining proprietary high-throughput screening assays with advanced generative AI models to enable _de novo_ antibody design and lead optimization. Absci describes a continuous six-week "lab in the loop" cycle, where AI-generated candidates are validated in a 77,000 square foot laboratory, enhancing model performance over time. The pipeline overview includes updates on ABS-201, an anti-prolactin receptor antibody program advancing to Phase 1/2a clinical trials for androgenetic alopecia and an anticipated Phase 2 trial for endometriosis. ABS-101, an anti-TL1A antibody, has reported Phase 1 interim results demonstrating an extended half-life compared to first-generation competitors, with partnership discussions underway. Early-stage programs in oncology and immunology are also in development. Absci's leadership team includes individuals with expertise in AI, drug creation, and pharmaceutical development. You can access the full presentation through the link below.